Nephros Research and Development Expenses 2010-2024 | NEPH

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Nephros research and development expenses from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Nephros Research and Development Expenses 2010-2024 | NEPH

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Nephros research and development expenses from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$195.6B
Stryker (SYK)	$137.3B
Boston Scientific (BSX)	$122.7B
Medtronic (MDT)	$114.6B
EssilorLuxottica (ESLOY)	$108.8B
Haleon (HLN)	$48.7B
Lonza Group Ag (LZAGY)	$46B
ResMed (RMD)	$35.1B
Koninklijke Philips (PHG)	$30.8B
Terumo (TRUMY)	$28.5B
Zimmer Biomet Holdings (ZBH)	$22B
Baxter (BAX)	$19.9B
Insulet (PODD)	$16.3B
Smith & Nephew SNATS (SNN)	$13.6B
Bio-Rad Laboratories (BIO)	$9.2B
Demant (WILYY)	$8.7B
BellRing Brands (BRBR)	$7.9B
Lantheus Holdings (LNTH)	$7.5B
ICU Medical (ICUI)	$4.3B
Haemonetics (HAE)	$4.1B
TG Therapeutics (TGTX)	$3.7B
Neogen (NEOG)	$3.6B
Prestige Consumer Healthcare (PBH)	$3.5B
GN Store Nord (GNNDY)	$3.5B
Perrigo (PRGO)	$3.5B
Envista Holdings (NVST)	$3.4B
QuidelOrtho (QDEL)	$3.1B
Agios Pharmaceuticals (AGIO)	$2.6B
Green Thumb Industries (GTBIF)	$2.2B
Maravai LifeSciences Holdings (MRVI)	$2.1B